PMVP
NASDAQPMV Pharmaceuticals Inc.
Price$1.14+0.04 (+3.65%)
02:15 PM07:45 PM
News · 26 weeks25+50%
2025-12-212026-06-14
Mix1390d
- SEC Filings5(38%)
- Insider5(38%)
- Other2(15%)
- Leadership1(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Stelzer Laurie4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Levine Arnold J4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Gallagher Carol Giltner4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Flowers Kirsten4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Baum Charles M4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- SECSEC Form 8-K filed by PMV Pharmaceuticals Inc.8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
- SECSEC Form 10-Q filed by PMV Pharmaceuticals Inc.10-Q - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECPMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
- SECSEC Form DEFA14A filed by PMV Pharmaceuticals Inc.DEFA14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECSEC Form DEF 14A filed by PMV Pharmaceuticals Inc.DEF 14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- PRPMV Pharmaceuticals Announces Board Chair TransitionPRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been appointed Chair of the Board, succeeding Rich Heyman, Ph.D., effective at the Company's 2026 Annual Meeting of Stockholders on June 4, 2026 (the "Meeting"). Dr. Heyman's term as a member and Chair of the Board will expire at the Meeting, and Dr. Heyman will not stand for reelection. Ms. Stelzer brings more than 25
- INSIDERSEC Form 4 filed by Chief Financial Officer Carulli Michael4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel & COO Ticktin Robert4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Chief Development Officer Jalota Deepika4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Mack David Henry4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- SECSEC Form S-8 filed by PMV Pharmaceuticals Inc.S-8 - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECPMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECSEC Form 10-K filed by PMV Pharmaceuticals Inc.10-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- PRPMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsEnrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumorsRezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027Cash, cash equivalents, and marketable securities of $112.9 million as of December 31, 2025 providing
- SECAmendment: SEC Form SCHEDULE 13D/A filed by PMV Pharmaceuticals Inc.SCHEDULE 13D/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
- PRNew England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid TumorsPRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM). The publication provides a summary of the Phase 1 safety and efficacy results across 77 patients. The study published in NEJM entitled, "Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y2
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
PMVP FAQ
7 questionsWhat does PMV Pharmaceuticals Inc. do?
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in...Where does PMVP stock trade?
PMV Pharmaceuticals Inc. (PMVP) is listed on NASDAQ.What sector and industry is PMVP in?
PMV Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PMV Pharmaceuticals Inc. go public?
PMV Pharmaceuticals Inc. (PMVP) completed its IPO in 2020.What are analysts saying about PMVP?
PMV Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $600.00 price target on 2024-11-08.What companies are similar to PMVP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PMVP side-by-side with any of them on Quantisnow.How can I track PMVP on Quantisnow?
Quantisnow aggregates PMV Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PMVP to receive live email and push alerts on every new disclosure.